Biotech wins hearts – and funding

Welcome to Tech in Asia’s free Saturday VC newsletter! Get full access to our subscribers-only premium content and other insightful analysis on the big and messy topics of Asia’s tech and startup community by registering here.

Hello reader,

Happy Valentine’s Day! Roses are red, violets are blue, sugar is sweet, and I have… some funding news for you.

The sector that has caught my attention this week is the biotech industry. Two of the top-funded companies on our list operate in the biotech sphere, developing solutions in areas like regenerative medicine and using AI to enhance drug discovery.

It’s pretty cool stuff. After all, health is wealth. Here’s to hoping that one of these firms will discover a cure for cancer one day – I think that’d be pretty neat.

You can find all other important investment deals from the last few days in our weekly funding news wrap-up.

Let’s dive into the biggest deals and M&A that have recently taken place.

— Stefanie

---

The biggest deals by market

🇦🇺 Firmus Technologies builds highly efficient AI infrastructure and AI factories. Based in Australia, it has raised US$70 million in strategic investment from Maas Group Holdings.

🇨🇳 Regend is a China-based biopharmaceutical company that focuses on the field of regenerative medicine. It has bagged US$50 million in series C funding from Hefei Hi-tech Venture Capital, Fuho Capital, Hefei Industry Investment Group, and Yuze Capital.

🇵🇭 GCash is a financial super app that lets users buy goods, pay bills, send money, and take out loans with just their mobile phones. Hailing from the Philippines, it has secured US$30 million in debt financing from the Asian Development Bank.

🇮🇳 Supertails, a digital pet care platform in India, has scored US$30 million in series B funding. Participating investors were Fireside Ventures, Nippon India Alternative Investments, Saama Capital, Titan Capital, and Venturi Partners.

🇰🇷 Galux is a biotech firm that leverages AI, physics, and chemistry to design and develop novel therapeutic drugs. Headquartered in South Korea, it has raised US$29 million in series B funding from Dayli Partners, InterVest, Korea Development Bank, Korea Investment & Securities, Mirae Asset Securities, NCORE Ventures, Pathway Partners, SL Investment Management, Sneak Peek Investments, and Yuanta Investment.

---

M&A

---

Startups that are raising funds

---

Behind the Glasswall

---

Get clarity across customer journeys

---

Exclusive listicles

---

Thoughtful reads